NEW YORK (GenomeWeb News) – Gene Network Sciences will process clinical data from Biogen Idec to identify targets and biomarkers for inflammation, GNS said today.
GNS will use the data to develop a forward-simulation model that Biogen will then license.
GNS uses massively parallel supercomputers to search through “vast amounts of raw human biological data” for causes of disease and information about disease treatment, the company said.
Specifically, GNS will use its Reverse Engineering/Forward Simulation platform with genomic, genetic, and clinical data from Biogen “to generate and score billions of hypotheses to discover new drug targets and biomarkers rapidly,” the firm said in a statement.
Financial terms of the agreement were not released.